Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: A phase II study

Supportive Care in Cancer

Volumn 19, Issue 5, 2011, Pages 697-701

  Rozzi, Antonio ^a   Nardoni, Chiara ^a   Corona, Michela ^a   Restuccia, Maria Rosa ^a   Fabi, Alessandra ^b   Bria, Emilio ^b   Minniti, Giuseppe ^c   Lanzetta, Gaetano ^a,c  

^a Istituto Neurotraumatologico Italiano   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c IRCCS NEUROMED   (Italy)

Author keywords

CINV; Glioblastoma; Oral; Palonosetron; Radiotherapy; Temozolomide

Indexed keywords

DEXAMETHASONE; PALONOSETRON; TEMOZOLOMIDE;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLIOBLASTOMA; HEADACHE; HUMAN; KARNOFSKY PERFORMANCE STATUS; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; SINGLE DRUG DOSE;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DACARBAZINE; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GLIOBLASTOMA; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; NAUSEA; QUINUCLIDINES; SEROTONIN ANTAGONISTS; VOMITING;

EID: 79958232710     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-010-0893-y     Document Type: Article

References (25)

1. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996 (Pubitemid 40349501)
2. Hesketh PJ, Kris MG, Grunberg SM et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103-109 (Pubitemid 27020563)
3. Grunberg SM, Osoba D, Hesketh PJ et al (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - an update. Support Care Cancer 13:80-84 (Pubitemid 40558162)
4. Christodolou C, Bafaloukos D, Kosmidis P et al (2001) Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 12:249-254 (Pubitemid 32223877)
5. Trudeau ME, Crump M, Charpentier D et al (2006) Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada-Clinical Trials Group (NCIC-CTG). Ann Oncol 17:952-956
6. Gogas H, Polyzos A, Stavrinidis I et al (2006) Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 17:1835-1841
7. Roila F, Hesketh PJ, Herrstedt J (2006) Antiemetic prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. Ann Oncol 17(1):20-28, Epub 2005 Nov 28 (Pubitemid 43033835)
8. Herrstedt J (2008) Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 5 (1):32-43
9. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis V.1.2007. Available at http://www.nccn.org/ professionals/physician-gls/PDF/antiemesis.pdf. Accessed August 3, 2008
10. Einhorn LH, Rapoport B, Koeller J et al (2005) Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 13:112-116 (Pubitemid 40558167)
11. Navari RM (2007) Prevention of emesis from multiple-day and high-dose chemotherapy regimens. J Natl Compr Canc Netw 5:51-59
12. Navari RM (2006) Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist. Future Oncol 2(5):591-602
13. Rubenstein EB, Slusher BS, Rojas C, Navari RM (2006) New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J 12(5):341-347 (Pubitemid 44564817)
14. Wong EHF, Clark R, Leung E et al (1995) The interaction of RS 25259-197, a potent selective antagonist, with 5-HT3 receptors in vitro. Br J Pharmacol 114:851-859
15. Miller RC, Galvan M, Gittos MW et al (1993) Pharmacological properties of dolasetron, a potent and selective antagonist at 5-HT3 receptors. Drug Dev Res 28:87-93 (Pubitemid 23041487)
16. Hutt AJ, SC TAN (1996) Drug chirality and its clinical significance. Drug 52(Suppl 5):1-12 (Pubitemid 26379061)
17. Gregory RE, Ettinger DS (1998) 5-HT3 receptors antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs 55:173-189
18. Eisenberg P, Figueroa-Vadillo J, Zamora R et al (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98:2473-2482 (Pubitemid 37466663)
19. Gralla R, Lichinitser M, Van der Vegt S et al (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570-1577 (Pubitemid 37304615)
20. Rubenstein EB, Gralla RJ, Eisenberg P et al (2003) Palonosetron (PALO) compared with ondansetron (OND) or dolasetron (DOL) for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV): combined results of two phase III trials. Proc Am Soc Clin Oncol 22(729):A2932
21. Aapro MS, Grunberg SM, Manikhas GM et al (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441-1449 (Pubitemid 44400384)
22. Buses KS, Joss RA, Piquet D et al (1993) Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double blind, placebo-controlled study. Ann Oncol 4:475-479
23. Rojas C, Stathis M, Thomas AG, Massuda EB, Alt J, Zhang J, Rubenstein E, Sebastiani S, Cantoreggi S, Snyder SH, Slusher B (2008) Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 107(2):469-478, Erratum in: Anesth Analg. 2008 Oct;107(4):1405
24. Einhorn LH, Brames MJ, Dreicer R, Nichols CR, Cullen MT Jr, Bubalo J (2007) Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 15(11):1293-1300, Epub 2007 Apr 14 (Pubitemid 47583451)
25. Musso M, Scalone R, Bonanno V, Crescimanno A, Polizzi V, Porretto F, Bianchini C, Perrone T (2009) Palonosetron (Aloxi®) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. Support Care Cancer 17(2):205-209, Epub 2008 Oct 7